linkedin post 2013-06-22 05:01:39

Uncategorized
NEW R&D MODEL needed for antibiotic innovation is proposed: public-private partnerships. We all know that we have over-used antibiotics. And that resistant strains (Superbugs) are emerging. And that the pipeline is sparse because Big Pharma has left the sector. This call for a new initiative is in line with other similar open innovation public-private initiatives worldwide and let's hope it is adopted. http://lnkd.in/cRt2Hb View in LinkedIn
Read More

linkedin post 2013-06-22 04:48:21

Uncategorized
POC DIAGNOSTICS that can act in minutes not days (after pathogen cultures) for serious enteric pathogens offer a significant advantage where speed and accuracy of diagnosis is key. The culture days are facing extinction. Similarly, growing vaccines in chicken's eggs, which takes a long time, is also facing extinction by new recombinant methods, combined with in Silico antigen selection. http://lnkd.in/enkNY8 View in LinkedIn
Read More

linkedin post 2013-06-21 05:20:45

Uncategorized
MICROCHIP FOR ANTIBIOTIC-RESISTANT pathogens. This innovative technology takes the guesswork out of antibiotic prescribing, because it determines which antibiotics a pathogen in a biological sample (such as blood or tissue) is resistant to. Like the technology that tests drug sensitivity of tumor cells in vitro (Vivia Biotech), it makes the drug target, not the patient, the test tube. A lovely advance that should be widely used. http://lnkd.in/ebAzE9 View in LinkedIn
Read More

linkedin post 2013-06-21 05:03:36

Uncategorized
NEW CONDUCTIVE MATERIALS make for electronics as wearable devices, no longer silicon-trapped. Clothes with embedded devices, phones, heart monitors, GPS, the list of the possible is infinite. Boundaries until recently limited by silicon-based electronics are being shattered. Smart walls, responsive buildings, it is open season for anybody with an imagination and curiosity. Imagine the possibilities and start your new company around one of them! http://lnkd.in/WUyrQU View in LinkedIn
Read More

linkedin post 2013-06-21 04:35:00

Uncategorized
LESS DISEASE TARGETS? That is the assumption in traditional Pharma strategy thinking. But reflect on this: firstly, less than 2% of the druggable human genome has been spoken for. Secondly, severe tropical diseases kill tens of millions annually. The first will open due to genetics and already is (ie: genetically tailored cancer meds). The second is about economics. But as climate change drives more diseases like Dengue Fever into places like Texas, this too will change. Tropical diseases are migrating. Increasingly on our doorstep, they will attract Pharma attention. Not just Mr Gates. http://lnkd.in/4kEv6V View in LinkedIn
Read More